Athira Pharma, Inc. Financials
This page shows Athira Pharma, Inc. (ATHA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 7 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Athira Pharma, Inc. passes 2 of 9 financial strength tests. 2 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Athira Pharma, Inc. generates $0.43 in operating cash flow (-$45.7M OCF vs -$105.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Athira Pharma, Inc.'s EBITDA was -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 1.4% from the prior year.
Athira Pharma, Inc. reported -$105.6M in net income in fiscal year 2025. This represents a decrease of 8.9% from the prior year.
Athira Pharma, Inc. earned $-24.70 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 880.2% from the prior year.
Cash & Balance Sheet
Athira Pharma, Inc. generated -$45.8M in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 52.9% from the prior year.
Athira Pharma, Inc. held $69.3M in cash against $0 in long-term debt as of fiscal year 2025.
Athira Pharma, Inc. had 9M shares outstanding in fiscal year 2025. This represents an increase of 139.1% from the prior year.
Margins & Returns
Athira Pharma, Inc.'s ROE was -380.0% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 163.8 percentage points from the prior year.
Capital Allocation
Athira Pharma, Inc. invested $17.5M in research and development in fiscal year 2025. This represents a decrease of 75.2% from the prior year.
Athira Pharma, Inc. invested $33K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents an increase of 0.0% from the prior year.
ATHA Income Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $2.8M-22.8% | $3.7M-14.9% | $4.3M | N/A | $17.9M-19.1% | $22.2M+4.3% | $21.2M | N/A |
| SG&A Expenses | $4.0M+11.5% | $3.6M-30.6% | $5.2M | N/A | $7.6M+28.9% | $5.9M-8.9% | $6.5M | N/A |
| Operating Income | -$6.9M+5.7% | -$7.3M+23.5% | -$9.5M | N/A | -$29.6M-5.7% | -$28.0M-1.2% | -$27.7M | N/A |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$6.6M+5.1% | -$7.0M+23.8% | -$9.1M | N/A | -$28.7M-7.0% | -$26.9M-2.0% | -$26.3M | N/A |
| EPS (Diluted) | $-1.68 | $-0.18+21.7% | $-0.23 | N/A | $-7.46-965.7% | $-0.70-1.4% | $-0.69 | N/A |
ATHA Balance Sheet
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $30.0M-15.5% | $35.5M-18.3% | $43.5M-26.0% | $58.8M-31.8% | $86.2M-22.5% | $111.3M-16.6% | $133.5M-16.7% | $160.2M |
| Current Assets | $27.0M-16.1% | $32.2M-19.2% | $39.9M-27.3% | $54.8M-33.1% | $82.0M-23.2% | $106.7M-17.0% | $128.6M-16.9% | $154.7M |
| Cash & Equivalents | $20.9M+5.0% | $19.9M-24.7% | $26.4M-45.5% | $48.4M-29.7% | $68.9M-6.7% | $73.8M-5.1% | $77.8M-14.1% | $90.6M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $3.2M-8.8% | $3.6M-42.4% | $6.2M-55.6% | $13.9M-51.4% | $28.7M+2.7% | $27.9M+4.5% | $26.7M-11.1% | $30.1M |
| Current Liabilities | $2.8M-6.5% | $3.0M-45.7% | $5.5M-58.2% | $13.1M-52.7% | $27.8M+3.2% | $26.9M+5.1% | $25.6M-11.2% | $28.8M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $26.8M-16.3% | $32.0M-14.3% | $37.3M-16.8% | $44.8M-22.1% | $57.6M-30.9% | $83.3M-21.9% | $106.7M-18.0% | $130.2M |
| Retained Earnings | -$428.9M-1.6% | -$422.3M-1.7% | -$415.3M-2.3% | -$406.1M-3.8% | -$391.1M-7.9% | -$362.4M-8.0% | -$335.5M-8.5% | -$309.2M |
ATHA Cash Flow Statement
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$4.7M+33.3% | -$7.0M+52.3% | -$14.7M+43.6% | -$26.0M-13.0% | -$23.0M-3.1% | -$22.3M+13.5% | -$25.8M+1.9% | -$26.3M |
| Capital Expenditures | N/A | N/A | N/A | $0 | $0-100.0% | $28K+460.0% | $5K | $0 |
| Free Cash Flow | N/A | N/A | N/A | -$26.0M-13.0% | -$23.0M-3.0% | -$22.4M+13.4% | -$25.8M+1.8% | -$26.3M |
| Investing Cash Flow | $5.7M+1182.1% | $441K+106.0% | -$7.4M-161.4% | -$2.8M-115.6% | $18.0M-32.1% | $26.6M+103.7% | $13.0M+104.1% | $6.4M |
| Financing Cash Flow | $0 | N/A | N/A | $34K+183.3% | $12K | N/A | N/A | $152K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
ATHA Financial Ratios
| Metric | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -24.7%-2.9pp | -21.8%+2.7pp | -24.5% | N/A | -49.9%-17.7pp | -32.2%-7.6pp | -24.7% | N/A |
| Return on Assets | -22.0%-2.4pp | -19.6%+1.4pp | -21.0% | N/A | -33.3%-9.2pp | -24.1%-4.4pp | -19.7% | N/A |
| Current Ratio | 9.70-1.1 | 10.81+3.6 | 7.26+3.1 | 4.18+1.2 | 2.95-1.0 | 3.97-1.1 | 5.03-0.3 | 5.37 |
| Debt-to-Equity | 0.120.0 | 0.11-0.1 | 0.17-0.1 | 0.31-0.2 | 0.50+0.2 | 0.34+0.1 | 0.25+0.0 | 0.23 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Athira Pharma, Inc. profitable?
No, Athira Pharma, Inc. (ATHA) reported a net income of -$105.6M in fiscal year 2025.
What is Athira Pharma, Inc.'s EBITDA?
Athira Pharma, Inc. (ATHA) had EBITDA of -$101.3M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Athira Pharma, Inc.'s return on equity (ROE)?
Athira Pharma, Inc. (ATHA) has a return on equity of -380.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Athira Pharma, Inc.'s free cash flow?
Athira Pharma, Inc. (ATHA) generated -$45.8M in free cash flow during fiscal year 2025. This represents a 52.9% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Athira Pharma, Inc.'s operating cash flow?
Athira Pharma, Inc. (ATHA) generated -$45.7M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Athira Pharma, Inc.'s total assets?
Athira Pharma, Inc. (ATHA) had $92.2M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Athira Pharma, Inc.'s capital expenditures?
Athira Pharma, Inc. (ATHA) invested $33K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Athira Pharma, Inc. spend on research and development?
Athira Pharma, Inc. (ATHA) invested $17.5M in research and development during fiscal year 2025.
What is Athira Pharma, Inc.'s current ratio?
Athira Pharma, Inc. (ATHA) had a current ratio of 1.88 as of fiscal year 2025, which is generally considered healthy.
What is Athira Pharma, Inc.'s debt-to-equity ratio?
Athira Pharma, Inc. (ATHA) had a debt-to-equity ratio of 2.32 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Athira Pharma, Inc.'s return on assets (ROA)?
Athira Pharma, Inc. (ATHA) had a return on assets of -114.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Athira Pharma, Inc.'s cash runway?
Based on fiscal year 2025 data, Athira Pharma, Inc. (ATHA) had $69.3M in cash against an annual operating cash burn of $45.7M. This gives an estimated cash runway of approximately 18 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Athira Pharma, Inc.'s Piotroski F-Score?
Athira Pharma, Inc. (ATHA) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Athira Pharma, Inc.'s earnings high quality?
Athira Pharma, Inc. (ATHA) has an earnings quality ratio of 0.43x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.